Evidence map›Paper›PMID 30615197›Full record

ArticleClinical and experimental immunology2019

Novel small molecule IL-6 inhibitor suppresses autoreactive Th17 development and promotes T

S I Aqel, E E Kraus, N Jena, V Kumari, M C Granitto, L Mao, M F Farinas, E Y Zhao, G Perottino, W Pei and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Targeting inerleukin-6 for renoprotection.Frontiers in immunology · 2024
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Role of Interleukin-17 in Acute Pancreatitis.Frontiers in immunology · 2021
    Review
  13. Observational
  14. Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19.International journal of molecular sciences · 2020
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

S I AqelDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
E E KrausDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
N JenaDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
V KumariDivision of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
M C GranittoNeuroscience Program, College of Arts and Sciences, The Ohio State University, Columbus, OH, USA.
L MaoDepartment of Medicinal Chemistry, University of Florida, Gainsville, FL, USA.
M F FarinasNeuroscience Program, College of Arts and Sciences, The Ohio State University, Columbus, OH, USA.
E Y ZhaoDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
G PerottinoNeuroscience Program, College of Arts and Sciences, The Ohio State University, Columbus, OH, USA.
W PeiDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
A E Lovett-RackeDepartment of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
M K RackeDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
J R FuchsDivision of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
C LiDepartment of Medicinal Chemistry, University of Florida, Gainsville, FL, USA.
Y YangDepartment of Neurology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.ORCID 0000-0002-3043-8463
The Ohio State University Wexner Medical Center · USThe Ohio State University · USUniversity of Florida · USFlorida State University · US

Funding

Small molecule in vivo probe development targeting the IL-6/STAT3 pathway for potential multiple sclerosis therapyR01NS088437 · NINDS · UNIVERSITY OF FLORIDA · PI LI, CHENGLONG, YANG, YUHONG · 2015 to 2017
$1.3M
NINDS NIH HHS R01 NS088437
6 · The paper itself

Abstract

Multiple sclerosis (MS) is the leading cause of non-traumatic neurological disability in the United States in young adults, but current treatments are only partially effective, making it necessary to develop new, innovative therapeutic strategies. Myelin-specific interleukin (IL)-17-producing T helper type 17 (Th17) cells are a major subset of CD4 T effector cells (T

Indexed as

Interleukin-6 InhibitorsAdoptive TransferAnimalsCD4-Positive T-LymphocytesEncephalomyelitis, Autoimmune, ExperimentalHumansInterleukin-6MiceMice, Inbred C57BLMice, TransgenicMultiple SclerosisMyelin SheathSignal TransductionSmall Molecule LibrariesSTAT3 Transcription FactorTh17 CellsInterleukin-6Interleukin-6 Inhibitorsinterleukin-6, mouseSmall Molecule LibrariesSTAT3 Transcription FactorIL-6multiple sclerosissmall molecule inhibitorsT cell encephalitogenicityTh17

Identifiers

PMID30615197
PMCPMC6468176
OpenAlexW2910173973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.